Drug · CHEMBL113

CAFFEINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. CAFFEINE. Drugs and targets, record CHEMBL113. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL113

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: CAFFEINE; ChEMBL
ChEMBL ID: CHEMBL113; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Caffeine component of anoquan, Caffeine component of cafergot, Caffeine component of darvon compound, Caffeine component of dhc plus, Caffeine component of esgic, Caffeine component of excedrin, Caffeine component of femcet, Caffeine component of fioricet, Caffeine component of fiorinal, Caffeine component of invagesic, Caffeine component of invagesic forte, Caffeine component of lanorinal, Caffeine component of medigesic plus, Caffeine component of migergot, Caffeine component of norgesic, Caffeine component of orphengesic, Caffeine component of orphengesic forte, Caffeine component of synalgos-dc, Caffeine component of synalgos-dc-a, Caffeine component of trezix, Caffeine component of triad, Caffeine component of wigraine, Nodoz, Pro-plus, Yeast-vite, Zanthine; ChEMBL
Other names: Anhydrous caffeine, Caffeine anhydrous, Caffeine melting point standard, Caffeinum, Coffeinum, Durvitan, FEMA NO. 2224, Guaranine, NSC-5036, Synalgos, Vivarin; ChEMBL
Other form: CAFFEINE CITRATE, CHEMBL1200569; Drugs and targets
DrugBank: DB00201; DrugBank
InChIKey: RYYVLZVUVIJVGH-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 7 of its 48 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets4

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
ADORA1	Adenosine receptor	Adenosine receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/134
ADORA2A	Adenosine receptor	Adenosine receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/135
ADORA2B	Adenosine receptor	Adenosine receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/136
ADORA3	Adenosine receptor	Adenosine receptor antagonist	ANTAGONIST	https://conductscience.org/library/genes/140

Source ChEMBL

Diseases48

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
migraine disorder	Approval	DailyMed	123	7	https://conductscience.org/library/drugs?q=MONDO_0005277
obesity disorder	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0011122
Low back pain	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=HP_0003419
Parkinson disease	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005180
neuropsychological test	Phase 1/2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=EFO_0003926
Apnea	Approval	DailyMed, EMA Human Drugs and PMDA	7	2	https://conductscience.org/library/drugs?q=HP_0002104
Headache	Approval	DailyMed	5	2	https://conductscience.org/library/drugs?q=HP_0002315
bronchopulmonary dysplasia	Phase 3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0019091
cocaine dependence	Phase 2/3	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005186
Pain	Approval	DailyMed	7	1	https://conductscience.org/library/drugs?q=HP_0012531

1 to 10 of 48Source Open Targets

See all 48 diseases

Trials229

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01248468	Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine	Phase 4	752	2012-07-30	caffeine	Its name	ClinicalTrials.gov
NCT03003000	Ibuprofen/Caffeine Lower Back or Neck Pain Study	Phase 3	635	2019-06-07	caffeine	Its name	ClinicalTrials.gov
NCT01929031	Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain	Phase 3	562	2016-11-16	caffeine	Its name	ClinicalTrials.gov
NCT05485805	A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pain After Dental Surgeries Compared to the Single Ingredients and to Placebo	Phase 3	541	2025-03-25	caffeine, naproxen sodium and caffeine	Its name	ClinicalTrials.gov
NCT00573170	TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults	Phase 3	375	2010-12-29	caffeine	Its name	ClinicalTrials.gov
NCT02863575	A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine	Phase 3	374	2019-04-08	caffeine	Its name	ClinicalTrials.gov
NCT01842633	Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache	Phase 3	365	2017-07-27	caffeine	Its name	ClinicalTrials.gov
NCT00826280	Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)	Phase 3	347	2011-10-21	caffeine	Its name	ClinicalTrials.gov
NCT01686646	Effects of Two Doses of a Common Cold Treatment on Alertness	Phase 3	240	2014-07-14	caffeine	Its name	ClinicalTrials.gov
NCT02461693	Evaluating the Role of Expectations in Response to Caffeine Consumption: An RCT		205	2017-07-12	caffeine	Its name	ClinicalTrials.gov

1 to 10 of 229

See all 229 trials

Comparisons in its trials35

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Caffeine vs Placebo: serious adverse events	0 of 103	0 of 102	205	NCT02461693	Trial comparisons
Paracetamol/Caffeine Tablet vs Paracetamol Powder: serious adverse events	0 of 71	0 of 71	142	NCT01466348	Trial comparisons
CPC Adminstration vs Placebo Administration: deaths from any cause	0 of 66	0 of 63	129	NCT04972123	Trial comparisons
CPC Adminstration vs Placebo Administration: serious adverse events	0 of 66	0 of 63	129	NCT04972123	Trial comparisons
Caffeine vs Placebo: Occurence of Post Extubatory Respiratory Adverse Events.	17 of 36	34 of 36	72	NCT00273754	Trial comparisons
Caffeine vs Placebo: Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo.	11 of 36	21 of 36	72	NCT00273754	Trial comparisons
Caffeine vs Placebo: serious adverse events	0 of 36	0 of 36	72	NCT00273754	Trial comparisons
Reference Product vs Test Product: serious adverse events	0 of 36	0 of 36	72	NCT02629354	Trial comparisons
Experimental vs Control: deaths from any cause	0 of 33	0 of 31	64	NCT03577730	Trial comparisons
Experimental vs Control: serious adverse events	2 of 33	4 of 31	64	NCT03577730	Trial comparisons

1 to 10 of 35

See all 35 comparisons in its trials

Papers from its trials114

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40550198	RESULT	1	PubMed
40318850	RESULT	1	PubMed
39848332	RESULT	1	PubMed
36364354	RESULT	1	PubMed
35274096	RESULT	1	PubMed
35187019	RESULT	1	PubMed
34024173	RESULT	1	PubMed
33633278	RESULT	1	PubMed
33585896	RESULT	1	PubMed
33397141	RESULT	1	PubMed

1 to 10 of 114

See all 114 papers from its trials

Tests in its trials23

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
1-Back Task	6	4	ConductCognition
2-Back Task	6	4	ConductCognition
Trail Making Test A	6	2	ConductCognition
Trail Making Test B	6	2	ConductCognition
Verbal Learning	4	2	ConductCognition
Go/No-Go Task	3	1	ConductCognition
Psychomotor Vigilance Task	3	2	ConductCognition
Rapid Visual Information Processing	3	3	ConductCognition
Stroop Color-Word Test	3	2	ConductCognition
Card Sorting Test (Berg)	2	1	ConductCognition

1 to 10 of 23

See all 23 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL113

GET https://conductscience.org/api/drugs/v1/CHEMBL113/diseases?page=2

API reference For AI assistants